Vendor Intelligence Report: Sunny sky peptides

Published 2 Jul 2026. 16-page investigative report on who is behind Sunny sky peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, Sunny sky peptides has 4 passes and 0 fails — an overall pass rate of 100%. That headline is real but narrow: the entire Finnrick record covers Tirzepatide, where identity and public-methodology pass status are favorable, while the file also flags fill-consistency and stricter-grading sensitivity that matter for dose-confidence buyers.

The buyer read is directional rather than blanket. For Tirzepatide, Sunny sky has better evidence than an untested seller and appears as a plausible B-tier option. For any other peptide, the report treats the catalog as ungraded; one product’s clean identity record does not authenticate a broader supply chain.

The non-lab file is where the risk profile sharpens. Website copy uses older operating-history cues, but the verified web trail begins in 2025; the primary domain is privacy-protected, the contact surface is a Gmail address and Hong Kong-numbered phone, and no named legal entity or personnel were identified in the searched public records. A China-oriented hosting stack supports the listed China posture, but not ownership, factory status, or recourse.

The reputation scan is quiet in both good and bad ways. The report did not find a coupon-code or influencer-referral apparatus, which reduces one common gray-market red flag. It also found little organic customer-review history, plus a similar privacy-protected domain that could create channel confusion unless the vendor publishes clearer official-channel controls.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data with the full Tirzepatide sample table, methodology-divergence chart, and rating trajectory
  • WHOIS history for sunnyskypeptide.com and the suspected sunnypeptides.com sister-domain record
  • Corporate identity review covering U.S./OpenCorporates dead ends, the Kunshan address, Gmail contact, and Hong Kong phone route
  • Channel-authentication checklist for avoiding similar-name domains and unauthenticated sales contacts
  • Promotion and reputation scan across X/web coupon searches, Reddit web search, Trustpilot, forums, and public social profiles
  • Material risk matrix separating Tirzepatide fill consistency, untested-catalog extrapolation, corporate accountability, and history-claim risk

Risk assessment

  • Tirzepatide fill-consistency risk — medium: Tirzepatide has 4 Finnrick passes and an 82.63% current rating, but field testing materials report sample-level fill variability; this concern is product-specific to Tirzepatide.
  • Untested-catalog extrapolation risk — medium: The Finnrick record covers Tirzepatide only (4 tests; 4 pass / 0 fail); no supplied Finnrick data supports other Sunny sky peptides products.
  • Corporate accountability risk — medium: No buyer-facing legal entity or named personnel were identified; WHOIS is privacy-protected and contact routes are a Gmail address plus a +852 phone number.
  • Misleading operating-history claims risk — medium: The site presents 2005-era and multi-year development claims, while sunnyskypeptide.com was registered 2025-05-13 and no older operation was verified.
  • Brand-confusion and channel-verification risk — medium: The official domain supplied is sunnyskypeptide.com, but a similar privacy-protected sunnypeptides.com exists and the vendor provides no verified official-channel or reseller list in the materials.